Myoinositol plus α-lactalbumin supplementation, insulin resistance and birth outcomes in women with gestational diabetes mellitus: a randomized, controlled study

Abstract To verify whether myo-inositol plus α-lactalbumin may reduce insulin resistance and excessive fetal growth in women with gestational diabetes mellitus. In a 12-month period, 120 women with a diagnosis of gestational diabetes mellitus were consecutively enrolled with an allocation of 1:1 in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rosario D’Anna, Francesco Corrado, Saverio Loddo, Giuseppe Gullo, Loretta Giunta, Antonino Di Benedetto
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/9cf4f6afb5e14d53ac8a8bfb542e37e5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9cf4f6afb5e14d53ac8a8bfb542e37e5
record_format	dspace
spelling	oai:doaj.org-article:9cf4f6afb5e14d53ac8a8bfb542e37e52021-12-02T17:32:58ZMyoinositol plus α-lactalbumin supplementation, insulin resistance and birth outcomes in women with gestational diabetes mellitus: a randomized, controlled study10.1038/s41598-021-88329-x2045-2322https://doaj.org/article/9cf4f6afb5e14d53ac8a8bfb542e37e52021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-88329-xhttps://doaj.org/toc/2045-2322Abstract To verify whether myo-inositol plus α-lactalbumin may reduce insulin resistance and excessive fetal growth in women with gestational diabetes mellitus. In a 12-month period, 120 women with a diagnosis of gestational diabetes mellitus were consecutively enrolled with an allocation of 1:1 in each group and randomly treated with myo-inositol plus α-lactalbumin plus folic acid (treated group) or folic acid (control group) for 2 months. Primary outcome was the variation of insulin resistance through the study evaluated by HOMA-IR. Secondary outcome was the evaluation, through the study, of fetal growth by ultrasound measurements of abdominal circumference centiles and estimated fat thickness. Some clinical outcomes were also considered. After 2 months, in the treated group, a significant reduction in insulin resistance (HOMA values 3.1 ± 1.4 vs 6.1 ± 3.4, p = 0.0002) and fetal growth was shown (Abdominal circumference centiles 54.9 ± 23.5 vs 67.5 ± 22.6, P = 0.006). Among clinical outcomes, a significant decrease in the rate of women who needed insulin (6.7% vs 20.3%, p = 0.03) and of pre-term birth (0 vs 15.2%, p = 0.007) was evidenced. A combination of myo-inositol and α-lactalbumin may reduce insulin resistance and excessive fetal growth. Clinical trial registration: ClinicalTrials.gov, http://www.clinicaltrials.gov , NCT 03763669, first posted date 04/12/2018; last posted date December 06/12/2018.Rosario D’AnnaFrancesco CorradoSaverio LoddoGiuseppe GulloLoretta GiuntaAntonino Di BenedettoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-5 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Rosario D’Anna Francesco Corrado Saverio Loddo Giuseppe Gullo Loretta Giunta Antonino Di Benedetto Myoinositol plus α-lactalbumin supplementation, insulin resistance and birth outcomes in women with gestational diabetes mellitus: a randomized, controlled study
description	Abstract To verify whether myo-inositol plus α-lactalbumin may reduce insulin resistance and excessive fetal growth in women with gestational diabetes mellitus. In a 12-month period, 120 women with a diagnosis of gestational diabetes mellitus were consecutively enrolled with an allocation of 1:1 in each group and randomly treated with myo-inositol plus α-lactalbumin plus folic acid (treated group) or folic acid (control group) for 2 months. Primary outcome was the variation of insulin resistance through the study evaluated by HOMA-IR. Secondary outcome was the evaluation, through the study, of fetal growth by ultrasound measurements of abdominal circumference centiles and estimated fat thickness. Some clinical outcomes were also considered. After 2 months, in the treated group, a significant reduction in insulin resistance (HOMA values 3.1 ± 1.4 vs 6.1 ± 3.4, p = 0.0002) and fetal growth was shown (Abdominal circumference centiles 54.9 ± 23.5 vs 67.5 ± 22.6, P = 0.006). Among clinical outcomes, a significant decrease in the rate of women who needed insulin (6.7% vs 20.3%, p = 0.03) and of pre-term birth (0 vs 15.2%, p = 0.007) was evidenced. A combination of myo-inositol and α-lactalbumin may reduce insulin resistance and excessive fetal growth. Clinical trial registration: ClinicalTrials.gov, http://www.clinicaltrials.gov , NCT 03763669, first posted date 04/12/2018; last posted date December 06/12/2018.
format	article
author	Rosario D’Anna Francesco Corrado Saverio Loddo Giuseppe Gullo Loretta Giunta Antonino Di Benedetto
author_facet	Rosario D’Anna Francesco Corrado Saverio Loddo Giuseppe Gullo Loretta Giunta Antonino Di Benedetto
author_sort	Rosario D’Anna
title	Myoinositol plus α-lactalbumin supplementation, insulin resistance and birth outcomes in women with gestational diabetes mellitus: a randomized, controlled study
title_short	Myoinositol plus α-lactalbumin supplementation, insulin resistance and birth outcomes in women with gestational diabetes mellitus: a randomized, controlled study
title_full	Myoinositol plus α-lactalbumin supplementation, insulin resistance and birth outcomes in women with gestational diabetes mellitus: a randomized, controlled study
title_fullStr	Myoinositol plus α-lactalbumin supplementation, insulin resistance and birth outcomes in women with gestational diabetes mellitus: a randomized, controlled study
title_full_unstemmed	Myoinositol plus α-lactalbumin supplementation, insulin resistance and birth outcomes in women with gestational diabetes mellitus: a randomized, controlled study
title_sort	myoinositol plus α-lactalbumin supplementation, insulin resistance and birth outcomes in women with gestational diabetes mellitus: a randomized, controlled study
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/9cf4f6afb5e14d53ac8a8bfb542e37e5
work_keys_str_mv	AT rosariodanna myoinositolplusalactalbuminsupplementationinsulinresistanceandbirthoutcomesinwomenwithgestationaldiabetesmellitusarandomizedcontrolledstudy AT francescocorrado myoinositolplusalactalbuminsupplementationinsulinresistanceandbirthoutcomesinwomenwithgestationaldiabetesmellitusarandomizedcontrolledstudy AT saverioloddo myoinositolplusalactalbuminsupplementationinsulinresistanceandbirthoutcomesinwomenwithgestationaldiabetesmellitusarandomizedcontrolledstudy AT giuseppegullo myoinositolplusalactalbuminsupplementationinsulinresistanceandbirthoutcomesinwomenwithgestationaldiabetesmellitusarandomizedcontrolledstudy AT lorettagiunta myoinositolplusalactalbuminsupplementationinsulinresistanceandbirthoutcomesinwomenwithgestationaldiabetesmellitusarandomizedcontrolledstudy AT antoninodibenedetto myoinositolplusalactalbuminsupplementationinsulinresistanceandbirthoutcomesinwomenwithgestationaldiabetesmellitusarandomizedcontrolledstudy
_version_	1718380138063724544

Myoinositol plus α-lactalbumin supplementation, insulin resistance and birth outcomes in women with gestational diabetes mellitus: a randomized, controlled study

Ejemplares similares